


June 2024

2024 Sustainability Report



Contents

- Section I. About bit.bio
Our Values
- Section II. Message from our CEO and Heads of Sustainability
- Section III. Our UN Sustainable Development Goals
- Section IV. ESG at bit.bio
- Section V. Looking Forward
- Section VI. Appendix

Section I. About bit.bio

bit.bio, a synthetic biology company, is democratising human cells to advance biomedical research (SDG9) and enable transformative treatments (SDG3). With Nobel Prize-winning science underpinning our understanding of cell identity as defined by unique combinations of transcription factors, our deterministic cell programming technology, opti-ox*, enables conversion of induced pluripotent stem cells (iPSCs) into any desired human cell type in a single step. This is achieved within days and at industrial scale, while maintaining exceptional purity and consistency. We are creating highly differentiated human cell products for research and drug discovery (ioCells) and cell therapy (txCells). Our growing commercial ioCells portfolio comprises ioWild Type Cells, ioDisease Model Cells and ioCRISPR-Ready Cells. Our cell therapy pipeline is currently focused on metabolism and endocrinology, immunology and neurology therapeutic areas.



Our Values

Purposeful: We are guided by our purpose, aligned to that of our namesake: coding biology for the benefit of humanity. We overcome our daily challenges by putting purpose first.

Ambitious: We are driven and ambitious in our creation of products that have value to society. Together we will change the world.

Collaborative and Trustworthy: Our purpose and mission hinge on leveraging our combined knowledge and skills. We value diversity and the power of collaboration.

Empirical: We embrace the scientific method and put facts above opinions. In the absence of data, we create it. We see the world as full of opportunities and approach it with a mindset of abundance.

Section II. Message from Our CEO and Heads of Sustainability



Mark Kotter
bit.bio CEO



Kathryn Corzo
President and
COO



Prof. Marie-Claire Cordonier Segger
Chair – Ethics &
Sustainability Board



Megan Doe
VP Portfolio Strategy &
Business Operations

bit.bio was built to make a difference and contribute to global sustainability from its very inception, “rewriting human health.” We believe that it is our responsibility to build a sustainable business from the ground up to protect the planet for future generations and to provide leadership on social responsibility and sustainability.

One of the most pressing issues of our time is the urgent need to tackle the climate crisis. We understand the gravity of this challenge and are fully dedicated to playing our part in addressing it by committing to the UN Race to Zero campaign. Through strategic investments in renewable energy, improvements in waste management practices, and the promotion of sustainable behaviors among our employees, we are actively working towards our goal of achieving net zero prior to the 2050 deadline.

We recognise that true sustainability extends beyond environmental stewardship – it encompasses a holistic approach to addressing social and economic challenges as well. That’s why we have aligned our purpose with the United Nations Sustainable Development Goals (SDGs), a framework that serves as a blueprint for a more sustainable future. Our sister company, Meatable, extends this work by tackling the ethical and environmental challenges of meat consumption.

We are pleased to present our first annual sustainability report, which provides an overview of our Corporate Sustainability Strategy and our progress towards each of our aligned SDGs. This report embodies our ongoing efforts to transparently communicate our goals and hold ourselves accountable to making progress each year.

We include information on each of our 3 primary aligned SDGs, which are at the core of what we do, and the 7 secondary SDGs that will guide our current operations and future strategy. At bit.bio, we don’t believe in siloing sustainability. Instead, it is integrated across our company. This report was created in consultation with senior leaders across our company, to ensure that our sustainability initiatives are woven into every aspect of our operations, in our labs and in our offices.

Collaboration and transparency are essential to creating a more sustainable future. We welcome feedback and engagement from our stakeholders on this report and on our sustainability efforts.

Our dedication to sustainability is not just a corporate initiative – it’s a core value that resonates with our employees, shareholders, and stakeholders alike. As we continue to grow and innovate, we remain steadfast in our commitment to advancing the SDGs and making a meaningful impact on the world.

We believe that by aligning our sustainability efforts with the UN SDGs and the COP26 goals, we can do our part to achieving a more sustainable, equitable, and resilient world for future generations. Thank you for your unwavering support and belief in our mission.

Section III. Our UN Sustainable Development Goals

We are leveraging our platform technologies to tackle the world’s biggest social and environmental challenges. We seek to lead on social responsibility and sustainability as we work towards the next generation of cures.

Our Corporate Sustainability Strategy



We believe it is our responsibility to build a sustainable business from the ground up to protect the planet for future generations. As a result, we have signed up to the United Nations Sustainable Development Goals (SDGs), with three primary goals and seven secondary objectives. These inform our Corporate Sustainability Strategy, which guides our daily operations and long-term growth.

Each SDG includes specific targets developed by the UN. We have identified the applicable targets for each bit.bio SDG, with progress towards each target measured through specific key performance indicators, and lead employees appointed to oversee advancement towards our goals.

This dedication to sustainability aligns with the values of our employees, shareholders, and external stakeholders. As we continue to expand, our Corporate Sustainability Committee will continuously update our strategy to ensure we remain at the forefront of sustainability and strive to make a positive impact on the planet. Our work on SDGs is not a side project; rather, is foundational to the future that bit.bio is working towards. It is with this understanding that we are voluntarily producing our Sustainability Report, to communicate our progress and provide a pathway for continuous improvement towards a truly sustainable future for generations to come.

3 GOOD HEALTH AND WELL-BEING



We leverage computation in biology to code cells for health.

bit.bio is driven and ambitious in our creation of a scalable technology platform, capable of producing pure and consistent batches of every type of human cell. We are democratising access to human cells for research, drug discovery, and cell therapies.

Good health is a fundamental human right. bit.bio is working towards this goal in two streams.

First, we are building a therapeutic pipeline of txCells to develop cell therapies for patients with high unmet need. Our lead candidate, bbHEP01 (encapsulated allogeneic txHepatocytes), is in development for acute liver diseases. Additionally, we are collaborating with BlueRock Therapeutics (a wholly owned independently operated subsidiary of Bayer AG) on regulatory T cell (Treg)-based cell therapies. The unlimited scalability of opti-ox will allow us to manufacture cell therapies up to two orders of magnitude below traditional approaches.

Second, with our growing commercial ioCells portfolio (ioWild Type, ioDisease Model, and ioCRISPR-Ready offerings), we are providing best-in-class research and drug discovery products to improve the therapeutic development process and transform human health. Thirty-eight marketed products are planned to comprise our launched portfolio by mid-2024.

We will continue to expand development of new cell types to drive our txCells and ioCells portfolios and progress SDG3 efforts.

9 INDUSTRY, INNOVATION AND INFRASTRUCTURE



We innovate discovery and partnerships.

Innovation is at the heart of what we do.

Our discovery platform and opti-ox technology are creating new industries, and we are expanding infrastructure to help achieve our purpose at scale. In 2023, we opened expanded labs with the help of Andrew Griffith, the UK's Minister of State for Science, Research and Innovation, doubling our available footprint and enhancing automation to quadruple our manufacturing output. We are investing both in places and people.

We continue to optimise our work processes to increase efficiencies and facilitate faster development of cell types. As we push the frontier of medicine with this new paradigm, we are committed to investing in sustainable, efficient technologies and creating environmentally sound processes. After joining the UN award-winning Green Impact Initiative in 2022 and winning bronze, bit.bio won gold in 2023 and platinum in 2024. We see investment in infrastructure and innovation as a commitment to a sustainable, healthy future and are dedicating the resources necessary to meet the gravity of this mission.



Andrew Griffith
Minister of State for Science, Research and Innovation at
the UK's Department for Science, Innovation and Technology

“ bit.bio's work [...] can transform future healthcare and its expanded facility to scale up their operation is another boost for the UK's leading engineering biology sector. ”

15 LIFE ON LAND



We revolutionise biomanufacturing and biomedical research.

Our scientists are leveraging the “operating system of life” via synthetic biology and cell programming and establishing a new bar for iPSC-derived cells with best-in-class mature functionality, unmatched biological consistency, and unlimited scalability.

As we seek to maximise our impact on human health, we seek to minimise our impact on the environment and promote fair and equitable sharing of its resources. In 2021, bit.bio joined the world’s efforts to tackle the climate crisis by signing on to the United Nations Race to Zero campaign. As members of the SME Climate Hub and the Climate Pledge, we immediately began integrating low-carbon practices into our business. Our state-of-the-art Green Building ensures sustainable energy, water, and waste usage, while our 100% vegetarian café measures and offsets food waste, demonstrating that our commitment to sustainability is at the very foundation of how and where we work. We are translating our pledges into action, for example by purchasing from sustainable suppliers, finding innovative ways to recycle in our labs, and offering electric car and bicycle schemes to staff. Our sister company Meatable is developing lab-grown meat to reduce the negative environmental impact of meat consumption.

bit.bio’s work aligns with international agreements to ensure the just and equitable sharing of benefits arising from the utilisation of genetic information. We will measure our progress through our ability to democratise ioCells and cell therapies at reduced costs.



Our work towards SDG15 is intertwined with our commitment to tackling the climate crisis.

bit.bio joined the world’s efforts against climate change by signing on to the United Nations Race to Zero campaign as part of COP 26 in Glasgow. We are committed to achieving net zero and beyond, ahead of the 2050 deadline. bit.bio is creatively and comprehensively evaluating our operations to ensure we protect our planet by:

- Halving our greenhouse gas emissions by 2030
- Achieving net zero before 2040
- Measure and report our progress on a yearly basis
- Implementing decarbonisation strategies in line with the Paris Agreement through interrogating each step of operations to guarantee energy and resource efficiency
- Neutralise any remaining emissions with additional, quantifiable, real, permanent, and socially beneficial offsets

Maximising Impact: Secondary Targets

In addition to our guiding primary SDGs, we have selected seven secondary SDGs to further expand our work towards a sustainable future and ensure sustainability is integrated within every aspect of our business.

2 ZERO HUNGER



Our sister company Meatable is using our patented technology to satisfy the world's appetite for meat without harming people, animals, or the planet. Lab-grown meat negates the ethical challenges posed by meat consumption, reduces the negative land impacts caused by animal production, and improves population access to nutritious protein sources.

In 2023, Meatable opened a new pilot facility, doubling the size of Meatable's previous office and lab space, marking another important step towards the planned 2025 retail launch. As the demand for meat is set to grow from 350 billion kg annually to more than 450 billion kg by 2050, cultivated meat could have a significant impact in reducing the meat industry's impact while helping to feed the world's growing population.

4 QUALITY EDUCATION



bit.bio is committed to supporting the next generation of innovators. We are emphasizing the importance of professional and personal development for young people and seeking to provide opportunities to as many talented young people as possible. We have trained multiple interns and funded doctoral students in our field. As we work together with the next generation of change-makers, we are prioritising a diverse and inclusive workforce.

Intern Highlights:

bit.bio's 2022 Carbon Report was drafted by a former intern who is now using the expertise he developed to further his career.

Another former intern created a bit.bio briefing series on ethical issues and the medical field and applied this knowledge to create an informational website for young adults about coronavirus and its impacts.

5 GENDER EQUALITY



bit.bio is passionate about ensuring women's full participation in our synthetic biology revolution. We are committed to equal distribution of employees and leadership opportunities by gender and ensuring gender pay parity. We have embedded these values into our Dignity at Work Policy.

Our Women in STEM sessions highlight the contributions of and challenges faced by women in research, and we celebrate women worldwide on our social media on International Women's Day.

In addition to promoting gender equality in our workforce, bit.bio is expanding its cell type portfolio to account for biological variation in diseases. For example, we market both female and male donor-derived ioMicroglia Cells, allowing scientists to conduct more customised research.

8 DECENT WORK AND ECONOMIC GROWTH



bit.bio was founded to democratise human cells to improve health around the world. As a purpose-driven company, we will play a leading role in the growth of the synthetic biology industry to ensure that related medical and economic benefits reach as many people as possible.

While we ambitiously work towards growing the industry, we emphasise creating a safe and secure working environment for our employees. Our Dignity at Work and Career Development Policy serve to codify these values and protections into the DNA of our company.

12 RESPONSIBLE CONSUMPTION AND PRODUCTION



bit.bio's supply chain will be an example for responsible, ethical production and consumption. As producers, we are committed to maximising safety and minimising environmental impact through developing detailed chemical waste policies and hope to broaden our own impact by engaging other companies in sustainable practices.

As consumers, waste minimisation is central to our sustainability goals. bit.bio places an emphasis on food waste reduction in our café and recycling improvements in our office and lab spaces. We engage our employees on these initiatives and more through our monthly Cell-fie newsletter, which advocates for sustainability improvements within our organisation.

13 CLIMATE ACTION



The climate crisis is one of the greatest challenges of our time and bit.bio is resolute in aligning our work with tackling climate change.

Achieving a low carbon future is integrated into every aspect of our operations, with adherence to our Race to Zero pledge acting as a central tenet of our corporate strategy. Every year, we will report on our progress to reaching net zero by 2040. To help achieve this goal, we are further fostering a sustainable work environment by empowering our employees to channel their environmental passion into action through our Green team. The monthly Cell-fie newsletter highlights these contributions and brings more employees into the action.

16 PEACE, JUSTICE AND STRONG INSTITUTIONS



Transparency, democratic decision-making, and honesty are foundational to bit.bio's work and mission. Every employee at bit.bio is guided by a detailed code of conduct and ethical code for research, anti-corruption and bribery policies, a whistleblower policy, and the highest of ethical standards. We have built channels into our operations from the ground up to ensure that each person at bit.bio has a voice and is empowered to contribute to bit.bio's direction and raise concerns if necessary. Based on research on best governance practices, we are instituting changes to optimise our employees' workflow for well-being and productivity and seeking to ensure transparency of our decision-making processes.

Section IV. ESG at bit.bio

bit.bio is pushing synthetic biology to a new frontier, and we understand the imperative to proceed with purpose. As we work towards a future in which our deterministically programmed human cells enable a new industry of biomedical innovation (SDG9) and a new generation of cures (SDG3), we are guided by an understanding of the environmental, social, and ethical gravity of our aspirations. Through engagement with our senior leadership, we have developed KPIs to track our corporate sustainability progress (see appendix) and guide our work. Our governance is intertwined with our mission to lead with our values and ethical codes.

Protecting our planet is not an afterthought to bit.bio, but rather, is ingrained in every aspect of our operations and strategy. Our deep commitment to tackling the climate crisis and protecting all life on land is evidenced through our work towards SDG 9, SDG 13, and SDG 15 and our participation in the UN Race to Zero pledge. We will measure and report our progress towards our environmental goals annually, with each subsequent year serving as a new opportunity to strengthen our commitment to protecting the planet.

To pursue our purpose, bit.bio has assembled a diverse team of pioneers. We are committed to creating an inclusive, safe work environment that values diversity and uplifts each employee. This commitment is embodied in our work to support women in STEM through mentorships and a strong emphasis on gender parity (SDG 5). We also recognise the impact our work will have on society and are committed to creating affordable life-saving treatments (SDG 3, 15).

Our Ethics & Sustainability Board was established to ensure ethical, independent oversight of company practices (SDG 16). The board's remit is to advise and recommend on ethics and sustainability for bit.bio's existing, emerging and prospective products, services and processes, policies and governance, partnerships and engagement opportunities in bit.bio's interests. The Chair of the Board has been with the company since day one to ensure that we build a purpose-driven organisation.


Codes to Live By

bit.bio has created our own, industry-leading policies. Our Code of Business Conduct and Ethics and Science, Research, and Conduct Ethics Policy are foundational to our operations and employee practices. These codes are supplemented by an Anti-corruption and Bribery policy, Dignity at Work Policy, and the Alcohol and Drug Misuse Policy, while our Whistleblowing Policy, Grievance Policy, Disciplinary Policy, and Career Development Policy all serve as mechanisms to support the integration of these values into all of bit.bio's work. bit.bio is creating a culture where every individual is treated with dignity and respect and is empowered and protected to voice their views.

Section V. Looking Forward

Our work to drive a healthier, more sustainable future is ongoing. As we continue to grow, we will remain committed to our sustainability goals and strive to make a positive impact on the planet. Together, we will work towards a cleaner, greener future for generations to come.

Every year, bit.bio will evaluate and measure our progress towards the primary and secondary SDGs that guide our work. The 2024 Sustainability Report will be the first of many, and we commit to reporting our achievements in our annual sustainability report.



Section VI. Appendix

2023 Carbon Emissions

We measure and track our emissions across three key areas, which are further tracked under Greenhouse Gas protocols.



Please find more information about GHG protocols [here](#).

Electricity & Gas

Kwh & m3 usage from separate meters at DHB

We track emissions from our own operations and eliminate them in due course. Our ambition is to eliminate all of our emissions.

We consumed **645,814 kWh of electricity** and **11,518 m3 of gas**, totalling **147.42 tonnes of CO₂ emissions**.



Data includes the shared used of air conditioning.
 145.31 tonnes: 645,814 kWh of electricity at 0.225 kgCO₂e/kWh. 2.11 tonnes: 11,518 kWh of natural gas
 Calculated by: <https://www.carbonfootprint.com/calculator>

Waste

KG of waste

We generated approximately **58,463kg of waste**.

Data from Babraham Campus.

Business Travel


CO₂ emissions

We track emissions from our business travel (flights and hotels) using our travel platform.

Total employee travel generated **486.8 tons of CO₂ emissions**.

CO₂ emissions

Total CO₂ emissions across all bookings.



Carbon Offsets

In addition to local and internal mitigation and resilience efforts that will help us to go carbon negative over time, bit.bio is investing in high impact and value international carbon reduction projects. Our chosen partners, The International Small Group and Tree Planting Program (TIST), Gold Standard, and Carbon Footprint, were selected by the staff together in a vote.



- Most CO₂ emissions from electricity/gas are offset internally, and our electricity and gas consumption is 100% REGO renewable certified. Therefore, we have adjusted our emissions from electricity/gas to be internally offset by 90%.
- Remaining emissions are offset externally, via strategically engaging with three offset beneficiaries outlined below. These partners and their respective weighting were selected by employees.
- We will complete these offsets by the end of 2024.

External offset partner	External offset amount (Ton)
TIST (50% weight)	251
Gold Standard (30% weight)	151
Carbon Footprint (20% weight)	100
Total	502

2040 roadmap and emission reduction initiatives

As we progress in our commitment to reduce carbon emissions, we are continuing to undertake initiatives to limit our carbon footprint. Select examples include commuting, office and laboratory.

Commuting

- Support hybrid working
- Promote commuting methods with lesser carbon footprints (e.g. electric vehicle scheme, subsidised bus pass, car sharing, cycle to work scheme)

Office

- Choose sustainable suppliers for office supplies
- Offer subsidised 100% vegetarian menu in café
- Implement new recycling schemes (e.g. crisp packages, batteries)

Laboratory

- Choose sustainable suppliers for consumables and reagents
- Implement glove and plastics recycling to avoid incineration
- Reduce carbon impact of shipping materials

Sample of KPIs tracked against SDGs committed to by bit.bio

bit.bio Relevant SDGs		bit.bio Contributions towards SDGs	KPI(s)	Timeframe
Primary Objectives				
3	Good Health & Well-Being			
3.2	By 2030, end preventable deaths of newborns and children under 5 years of age, with all countries aiming to reduce neonatal mortality to at least as low as 12 per 1,000 live births and under-5 mortality to at least as low as 25 per 1,000 live births	Develop cell therapies to treat patients with relevant diseases	Number of cell therapy programs that address relevant diseases, of which x number are particularly relevant to children Number of patients treated with our cell therapy products, of which x number are children under 5	Longer term Longer term
		Develop ioCells (wild types and disease models) that facilitate drug discovery efforts in relevant diseases	Number of marketed ioCells products that relate to relevant diseases, of which x number are relevant to children Number of customers using ioCells to research relevant diseases, of which x number are relevant to children	Longer term Longer term
3.4	By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being	Develop cell therapies to treat patients with relevant diseases	Number of cell therapy programs that address relevant diseases Number of patients treated with our cell therapy products	Longer term Longer term
		Develop ioCells (wild types and disease models) that facilitate drug discovery efforts in relevant diseases	Number of marketed ioCell products that relate to relevant diseases Number of customers using ioCells to research relevant diseases	Longer term Longer term
3.5	Strengthen the prevention and treatment of substance abuse, including narcotic drug abuse and harmful use of alcohol	Develop cell therapies to treat patients with relevant diseases (e.g., liver failure, cirrhosis)	Number of cell therapy programs that address relevant diseases Number of patients treated with our cell therapy products	Longer term Longer term
		Develop ioCells that facilitate drug discovery efforts in relevant diseases	Number of marketed ioCells products related to relevant diseases Number of customers using ioCells to research relevant diseases	Longer term Longer term
3.8	Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all	Develop cell therapies at reduced cost (1-2 orders of magnitude lower than current cell therapies) to facilitate lower prices and democratisation of access	Cell therapy COGS Cell therapy pricing and reimbursement strategy	Longer term Longer term
3.b	Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all	Develop cell therapies to treat patients with relevant diseases Develop cell therapies at reduced cost (1-2 orders of magnitude lower than current cell therapies) to facilitate lower prices and democratisation of access Develop ioCells (wild types and disease models) that facilitate drug discovery efforts in relevant diseases, and basic research	Number of cell therapy programs that address relevant diseases Number of patients treated with our cell therapy products Cell therapy COGS Cell therapy pricing and reimbursement strategy Number of marketed ioCells products that relate to relevant diseases Number of customers using ioCells to research relevant diseases Number of research partnerships with other labs Number of peer reviewed published studies mentioning our research Number of PhD students funded	Longer term Longer term Longer term Longer term Longer term Longer term Longer term Longer term Longer term Longer term
9	Industry, Innovation and Infrastructure			
9.1	Develop quality, reliable, sustainable and resilient infrastructure, including regional and transborder infrastructure, to support economic development and human well-being, with a focus on affordable and equitable access for all	Establish scientific infrastructure for bit.bio to support human well-being	Number of lab and other work stations Discovery Platform Development (increase in number of perturbations)	Nearer term Nearer term
9.4	By 2030, upgrade infrastructure and retrofit industries to make them sustainable, with increased resource-use efficiency and greater adoption of clean and environmentally sound technologies and industrial processes, with all countries taking action in accordance with their respective capabilities	Implement Green Impact policies and practices at bit.bio including resource-use efficiency and clean and environmentally sound technologies and processes	Green Impact Award programmes and progress	Nearer term
9.5	Enhance scientific research, upgrade the technological capabilities of industrial sectors in all countries, in particular developing countries, including, by 2030, encouraging innovation and substantially increasing the number of research and development workers per 1 million people and public and private research and development spending	Lead scientific research, encouraging innovation and increasing research and development workers in UK and countries of operation	Number of R&D employees R&D spend Number of cell type programs at each stage in the clinical pipeline	Nearer term Nearer term Nearer term
15	Life on Land			
15.1*	By 2020, ensure the conservation, restoration and sustainable use of terrestrial and inland freshwater ecosystems and their services, in particular forests, wetlands, mountains and drylands, in line with obligations under international agreements	Support the development of lab grown meat via Meatable to 1) negate ethical issues and 2) reduce negative land impacts related to animal production, and to 3) improve population access to nutritious protein sources	Kilograms of lab-grown meat sold by Meatable	Longer term
15.5	Take urgent and significant action to reduce the degradation of natural habitats, halt the loss of biodiversity and, by 2020, protect and prevent the extinction of threatened species	Reduce carbon emissions to zero in keeping with the UN Race to Zero campaign - internal and external offsets Purchase from sustainable suppliers Reduce waste and increase recycling (e.g., plastics, lab gloves) Offer 100% vegetarian menu in café Support the development of lab grown meat via Meatable to reduce the land impact of animal production	Publish annual carbon report, documenting internal and external (paid) offsets to take emissions to zero Percent of purchases that are from identified sustainable suppliers Kilograms of collected waste Number of recycling streams Percent of menu that is vegetarian Kilograms of lab-grown meat sold by Meatable	Nearer term Nearer term Nearer term Nearer term Nearer term Longer term
15.6	Promote fair and equitable sharing of the benefits arising from the utilization of genetic resources and promote appropriate access to such resources, as internationally agreed	Develop cell therapies at reduced cost to facilitate lower prices and democratisation of access Develop ioCells (wild types and disease models) that facilitate drug discovery efforts and sell at benchmarked cost Partner with other companies / foundations to develop cell therapies and ioCells for serious diseases with unmet needs	Cell therapy COGS Cell therapy pricing and reimbursement strategy Number of marketed ioCells products Number of customers using ioCells Number of partnerships	Longer term Longer term Nearer term Nearer term Nearer term
15.a	Mobilize and significantly increase financial resources from all sources to conserve and sustainably use biodiversity and ecosystems	Reduce carbon emissions to zero in keeping with the UN Race to Zero campaign - internal and external offsets Purchase from sustainable suppliers Offer 100% vegetarian menu in café	Publish annual carbon report, documenting internal and external (paid) offsets to take emissions to zero Percent of purchases that are from identified sustainable suppliers Percent of menu that is vegetarian	Nearer term Nearer term Nearer term

* In collaboration with Meatable